ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Fujifilm to raise output of Avigan to 300,000 sets by September

Anti-flu drug being tested as treatment for the new coronavirus

Fujifilm expects to raise output of Avigan up to 100,000 treatment courses by July 2020.   © Reuters

TOKYO (Reuters) -- Japan's Fujifilm Holdings Corp said it has expanded manufacturing capacity to "significantly increase" production of its anti-flu drug Avigan that is being tested as a treatment for COVID-19.

Fujifilm expects to increase the production of Avigan up to 100,000 treatment courses by July 2020, about 2.5 times more compared to the beginning of March when the company first began its current production run, and then to 300,000 by September, it said in a statement on Wednesday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more